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Lung cancera b s t r a c t
Lung cancer is one of the most common causes for cancer-related death. Previous studies suggested
that uncontrolled cell proliferation induced by activation of pro-cancer genes or inhibition of cancer
suppressor genes plays an important role in the pathogenesis of lung cancer. Here, we demonstrate
that miR-150 is aberrantly upregulated in lung cancer tissue and negatively correlates with the
expression of the proapoptotic gene p53 but not EGR2. We show that miR-150 speciﬁcally targets
the 30-UTR of p53 and regulates its expression. Inhibition of miR-150 effectively delays cell prolifer-
ation and promotes apoptosis, accompanied by increased p53 protein expression. Our data reveals
the mechanisms underlying miR-150 regulated lung cancer pathogenesis, which might be beneﬁcial
for lung cancer therapy.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Lung cancer, resulting from uncontrolled proliferation of cells
in the lung, was one of the most common human cancers that
had primary etiologies of both genetic [1] and environmental
[2] origin. Approximately 85% of lung cancers were caused by
long-term exposure to tobacco smoke, whereas the remaining
cases resulted from a combination of genetic factors, air
pollution, secondhand smoke, and other components [3–5].
Pathologically, most lung cancer cases were carcinomas, which
arised from epithelial cells, and non-small cell lung cancer
(NSCLC) accounted for over 80% of these cases [6]. Systematic
analyses of expression levels of both genes and proteins involved
in the pathogenesis of lung cancer had been performed, and
thousands of genes and proteins had been identiﬁed to be cru-
cial in the complex signaling network of carcinogenesis [7–9].
However, the underlying mechanisms of NSCLC were still poorly
understood.
MicroRNAs (miRNAs), small, non-coding RNAs, bond to speciﬁc
complimentary recognition sequences in the 30-untranslated re-
gion (UTR) mRNA sequence of target genes, resulting in inhibitionof translation, degradation, and gene silencing [10,11]. miRNAs
played critical roles in many diverse biological and pathological
processes, such as cell proliferation, migration, apoptosis, and
the pathogenesis of cancer [12]. The roles of miRNAs in lung can-
cer had been widely studied, and the 3 best-known regulators of
miRNA biogenesis and function, Dicer, DGCR8, and Drosha, were
disrupted in lung cancer [13]. Mounting evidence showed that
miRNAs were dysregulated in lung cancer and might serve as
oncogenes or tumor suppressors during tumorigenesis [14]. By
using miRNA microarrays, many miRNAs had been reported to
be aberrantly expresssed in lung cancer tissues [15,16]. Among
them, miR-150 was substantially upregulated. miR-150 was lo-
cated on chromosome 19q13 and played an essential role in
hematopoiesis [17,18]. Recent studies reported that miR-150 also
correlated with many cancers. For example, miR-150 negatively
regulated the proapoptotic gene EGR2, which in turn promoted
gastric cancer cell proliferation [19]. However, how did miR-150
regulate the tumorigenesis in lung cancer was still poorly
understood.
We showed that miR-150 was highly expressed in the tumor
tissues of NSCLC patients and was negatively correlated with
expression of the proapoptotic gene P53, but not EGR2. We also
showed that miR-150 suppressed the translation of P53 and in-
duced proliferation, while inhibiting apoptosis, in the NSCLC cell
line A549. Application of miR-150 inhibitor that speciﬁcally antag-
onizes miR-150 effectively suppressed cell proliferation and pro-
moted apoptosis, which was accompanied by increasing P53
protein expression.
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2.1. Samples
42 pairs of NSCLC and corresponding non-cancerous lung tis-
sues were used in this study. This study was approved by the Ethics
Committee of Huazhong University of Science and Technology, and
all participants had signed the informed written consent.
2.2. Plasmids
MiR-150 and the control vector were purchased from GeneCo-
poeia (Catalig#HmiR0306-MR03, Guangzhou, China). Human P53
construct was gift by Dr. Wang from Zhongnan University. The
miR-150 inhibitor and the scramble control were from RiboBio
(Catalog#miR20000451–1-5, Guangzhou, China). shRNA that spe-
ciﬁc to human P53 (TGCGTGTGGAGTATTTGGATG) and its scram-
bled control were synthesized by Shanghai Shenggong Biotech
(Shanghai, China).
2.3. Real time quantitative PCR
Total RNA was extracted from cells or lung tissue samples with
Trizol (Invitrogen, NY, USA). Then, 1 lg RNA was reversely-tran-
scribed into cDNA with reverse transcriptase kit (TAKARA, Dalian,
China). Real-time quantitative PCR was performed on a Stepone
Plus system (Invitrogen, NY, USA) using SYBR green PCR master
mix (TAKARA, Dalian, China). The cDNA was used for real-time
PCR of EGR2, P53, and the endogenous control b-actin. EGR2: sense
50-GCTGACACGGCACATCC-30; antisense 50-ACAGTAGTCACAGG
CGAAGG-30, P53: sense 50-GAGGTTGGCTCTGACTGTACC-30; anti-
sense 50-CCTCATTCAGCTCTCGGAAC-30, b-actin: sense 50-CGTGGAC
ATCCGCAAAGA-30; antisense 50-TCGTCATACTCCTGCTTGCTG-30.
MicroRNAs preparation and cDNA reverse transcription were pre-
pared using a MicroRNA Extraction Kit (Tiangen, Beijing, China).
Primers of microRNAs and the endogenous control of U6 snRNA
were purchased from Genecopiea (Guangzhou, China).
2.4. Western blotting
Lung tissues were homogenized in Western buffer containing
10 mM Tris–Cl; 1 mM phenylmethylsulfonyl ﬂuoride (PMSF);
1 mM sodium ortho-vanadate (Na3VO4); 1 mM edetic acid;
1 mM benzamidine; 50 mM sodium ﬂuoride (NaF); and 10 lg/
ml each of leupeptin, aprotinin, and pepstatin A. Three volumes
of the homogenate were added to one volume of a pH 7.6
extraction buffer, including 8% sodium dodecyl sulfate (SDS),
40% glycerol, and 200 mM Tris–Cl. Cell lysates were prepared
by using 2 SDS lysis buffer, consisting of 0.1 M Tris (pH 6.8),
20% glycerol, and 0.4% SDS. The protein concentration was mea-
sured by using a bicinchoninic acid (BCA) Protein Assay Kit
(Pierce, IL, USA). Equal amounts of proteins were loaded in
SDS–polyacrylamide gels and transferred to polyvinylidene ﬂuo-
ride membranes. Following blocking with 3% non-fat dry milk
for 0.5 h at room temperature, the membranes were incubated
overnight at 4 C with primary antibodies (EGR2, cata-
log#ab43020, 1:1000 for Western blot; P53, catalog#ab26,
1:1000 for Western blot; b-actin, catalog#ab6276, 1:2000 for
Western blot; all from Abcam). The blots were incubated with
horseradish peroxidase (HRP) labeled anti-mouse or anti-rabbit
immunoglobulin G (1:5000) at 37 C for 1hr, visualized with a
chemiluminescent substrate kit (Pierce, IL, USA), and were fur-
ther exposed to a CL-XPosure ﬁlm. The blots were scanned and
analyzed by using Kodak Digital Science 1D system (Eastman Ko-
dak Company, NY, USA).2.5. Dual luciferase assay
A549 and Calu-1 cells were cultured in a 96-well plate, 3000
cells per well. The human P53 wild type or mutated 30 UTR se-
quences were cloned into the psiCHECK-2 vector. After 24 h incu-
bation, the cells were treated with a co-transfection consisting of
35 ll serum-free medium, 0.5 ll Lipofectamine 2000 (Invitrogen,
NY, USA), 0.04 lg psiCHECK-2-vector-P53, and 0.12 lg miR-150
per well. Renilla luciferase or the control vector was used as a neg-
ative control. After 4 h incubation, 150 ll serum-containing med-
ium was added to the wells, and incubated for 48 h. Both the
Renilla and the Fireﬂy luciferase activity were detected by using
the Dual-Luciferase Reporter 1000 Assay System (Promega, WI,
USA).
2.6. CCK8 assay
Cells (5  105 cells/ml) were transfected with miR-150 or the
control vector for 48 h. Then each well was added with 10 ll
CCK-8 solution, and was incubated for 4 h at 37 C. The absorbance
was measured at 450 nm using a microplate reader (Promega, WI,
USA).
2.7. Flow cytometry
Cells were loaded in 6-well plates and transiently transfected
with miR-150 and the control vector. The cells were harvested
after 48 h transfection, and washed with PBS twice. The cells were
resuspended in 1 Binding Buffer, and 10 ll of Propidium Iodide
Solution, and 5 ll of Annexin FITC Conjugate was added to each
cell suspension, separately. The stained cells (1  105) were ana-
lyzed with a ﬂow cytometer (FACScalibur, NY, USA).
2.8. Ethics statement
The Huazhong University of Science and Technonlogy, Tongji
hospital Review Broad approved the study and participants all gave
informed consent by verbal.
2.9. Statistical analysis
Data are expressed as mean ± S.E. Differences were tested using
Student t-test and correlation analysis was tested by Pearson’s cor-
relation analysis. P < 0.05 was considered signiﬁcant.
3. Results
3.1. miR-150 was negatively correlated with P53 in the cancerous
tissue of NSCLC patients
To explore the possible role of miR-150 in the pathogenesis of
NSCLC, the expression proﬁles of miR-150 in the tumor tissue of
NSCLC patients were examined by using real-time quantitative
PCR. We found that levels of miR-150 increased approximately
3.5-fold above that found in normal tissue, which was consistent
with previously reported data [15]. Concurrently, we also found
that miR-95, miR-126, and miR-451 were dysregulated in the tu-
mor tissue. Among them, dysregulation of miR-150 was the most
prominent (Fig. 1A).
To determine how this increase in miR-150 expression might
promote tumorigenesis, we hypothesized that miR-150 regulated
cell proliferation and apoptosis via its predicted target genes, P53
and EGR2, predicted by Targetscan 6.2 (http://www.target-
scan.org/) and microRNA.org (http://www.microrna.org/), and
miRSearch 2.0 (http://www.exiqon.com/miRSearch). mRNA levels
Fig. 1. miR-150 was negatively correlated with P53 expression in NSCLC patients. (A) Expression levels of several miRNAs were compared between normal control and NSCLC
patients using RT-PCR. Relative expression levels of the miRNAs were normalized to the endogenous control, U6. (B) EGR2 and P53 mRNA levels were normalized to b-actin.
(C) EGR2 and p53 protein levels were determined by Western blotting, and (D) the relative intensity of the protein bands was analyzed. (E) miR-150 levels negatively
correlated with the relative p53 protein levels. ⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001 compared with control. All data represent the results of three independent experiments.
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(Fig. 1B); however, the protein levels of P53 were downregulated
whereas protein levels of EGR2 were not changed (Fig. 1C and D).
As miR-150 expression was negatively correlated with the protein
levels of P53 (Fig. 1E), we hypothesized that miR-150 might regu-
late the translation of P53.
3.2. miR-150 speciﬁcally targeted P53 in the NSCLC cell line A549
To determine if P53 was a target of miR-150, we performed se-
quence analysis and found that the P53 mRNA sequence contained
a conserved miR-150 binding site in its 30-UTR region. Both wild-
type and mutant P53 30-UTR fragment were cloned and inserted
into a luciferase reporter system. We found that the wild-type re-
porter exhibited apparent inhibition when co-expressed with miR-
150 in the NSCLC cell line A549, whereas the mutant sequence did
not (Fig. 2A). These data indicated that miR-150 directly targeted
P53.
To further verify this direct targeting, we overexpressed miR-
150 in A549 cells and examined the protein levels of P53 using
Western blot analysis. We found that upregulation of miR-150
expression led to a signiﬁcant decrease in P53 protein levels,
whereas inhibition of miR-150 (Fig. 2D) resulted in an obvious ele-
vation (Fig. 2B and C). These results indicated that P53 was the
functional target of miR-150 in A549 cells.3.3. miR-150 promoted cell proliferation of NSCLC cells by inhibiting
P53
To examine the potential role of miR-150 in tumor cell prolifer-
ation, we performed a cell proliferation analysis. We found that
A549 cells overexpressing miR-150 showed obvious increases in
cell proliferation, whereas concomitant overexpression of P53
effectively suppressed this proliferation (Fig. 3A and B). To explore
whether the effect of miR-150 on cell proliferation is P53 depen-
dent or not, we constructed an efﬁcient shRNA that speciﬁc target
human P53 gene (Fig. 3C). We found shRNA-P53 abolish the cell
proliferation inhibition induced by miR-150 inhibitor (Fig. 3D).
Meanwhile, in another type of NSCLC cell line, Calu-1, we also
found that overexpression of P53 retards the cell proliferation
caused by miR-150 and knock down P53 arrest the effect of miR-
150 inhibitor (Fig. 3E and F). Furthermore, inhibition of miR-150
promoted apoptosis in A549 cell lines (Fig. 4). These results indi-
cated that upregulation of miR-150 increased the cell proliferation
that was normally suppressed by P53 in NSCLC cells.
4. Discussion
In this study, we screened for multiple lung-enriched miRNAs in
NSCLC patients and found that the expression levels of miR-150
were signiﬁcantly upregulated in NSCLC tissues. We also found
Fig. 2. miR-150 speciﬁcally targeted P53 in the NSCLC cell line A549. (A) The P53 30-UTR and corresponding mutated fragments were independently inserted into a
psiCHECK2 vector. Relative luciferase activity was detected after cotransfection of a miR-150 or control vector with the above reporter constructs in A549 cells. (B) A549 cells
were transfected with the miR-150 or control vector for 48 h. P53 protein levels were measured by Western blotting and normalized to endogenous b-actin protein levels. (C)
A549 cells were transfected with a miR-150 inhibitor or control for 48 h. P53 protein levels were measured byWestern blotting and normalized to endogenous b-actin protein
levels. (D) Effect of miR-150 inhibitor was validated by quantitative real time PCR, and expression of miR-150 was measured. ⁄P < 0.05 compared with control, ⁄⁄P < 0.01
compared with wild-type cotransfection with vector. All data represent the results of three independent experiments.
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protein levels of P53, but not EGR2. By using a luciferase expres-
sion system, we found that P53 is speciﬁcally targeted by miR-
150. Overexpression of miR-150 promoted cell proliferation,
whereas overexpression of wild-type P53 antagonized this effect.
Inhibition of miR-150 suppressed cell proliferation and promoted
apoptosis. Our data illustrate the possible role of miR-150 and
P53 expression in the pathogenesis of NSCLC.
Many miRNAs had been found to be highly expressed in lung
cancer tissues and suppress target genes that played important
roles in cancer development [13]. For example, let-7 miRNAs neg-
atively regulated the oncogenes RAS [20], myc [21], and HMGA2
[22], which were signiﬁcantly correlated with a high risk for NSCLC
in moderate smokers [23]. On the other hand, some miRNAs acted
to inhibit cancer development. For instance, miR-34a, downregu-
lated in human lung cancer, could arrest cancer cells at the G1
phase, and inhibit proliferation [24]. MiR-150 was linked with a
number of cancers and was thought to promote cancer cell prolif-
eration in gastric cancer. It had also been found to be overexpres-
sed more than 50-fold in osteosarcoma [25]. Studies suggested that
miR-150 might serve as a potential biomarker for the prognosis
and therapeutic outcome of colorectal cancer [26] and MLL-associ-
ated leukemia [27]. In a previous report, miR-150 was found to be
upregulated in lung cancer tissue, which was concordant with the
ﬁndings of our present study.Although miR-150 was known to be upregulated in NSCLC and
anta-miR-150 treated mice display suppressed tumor growth [28],
while its detail roles and downstream targets were not clear. In
this study, we identiﬁed that P53 was a target of miR-150. As a tu-
mor suppressor, P53 limited proliferation by arresting cells in
either G1 or G2 phase and inducing apoptosis in response to cellu-
lar stress [29,30]. Disruption of P53 levels could promote tumor
progression and inhibit apoptosis, but elevate the DNA damage
[29,31]. Both transcription-dependent and transcription-indepen-
dent mechanisms were involved in P53-promoted cell death,
which acted in concert to ensure that apoptosis proceeded efﬁ-
ciently. Transcriptionally, p53 controled the expression of the
Bcl-2 family [32], Apaf-1 [33], Fas/CD95 [34], PTEN [35], and oth-
ers. Redistribution of P53 in the mitochondria preceded the release
of cytochrome c and caspase activation and only occured during
P53-dependent cell death. Directly targeting of P53 to the mito-
chondria could promote apoptosis in P53-deﬁcient cells, suggest-
ing that this redistribution of P53 was proapoptotic [36]. We
showed that the protein levels of P53 were regulated by miR-
150. As expression of miR-150 did not suppress the mRNA levels
of P53, we concluded that miR-150 inhibits the translation, but
not the transcription, of P53. Previous report suggested that in
anta-miR-150 treated tumor tissue, the expression of P53 is in-
creased, and indicated P53 is the potential downstream target of
miR-150 but the direct evidences were not provided [28]. By using
Fig. 3. miR-150 promotes cell proliferation. (A) A549 cells were transfected with a miR-150 or control vector and incubated for 48 h. Cell proliferation was measured by a
CCK-8 assay. (B) A549 cells were transfected with the miR-150 or control vector, along with P53 or its control vector, and incubated for 48 h. Cell proliferation was measured
by a CCK-8 assay. (C) Effect of P53 shRNA was detected by Western blot. (D) A549 cells were transfected with the miR-150 inhibitor (anti-miR-150) or control vector, along
with P53 shRNA or its control vector, and incubated for 48 h. Cell proliferation was measured by a CCK-8 assay. (E) Calu-1 cells were transfected with the miR-150 or control
vector, along with P53 or its control vector, and incubated for 48 h. Cell proliferation was measured by a CCK-8 assay. (F) Calu-1 cells were transfected with the miR-150
inhibitor (anti-miR-150) or control vector, along with P53 shRNA or its control vector, and incubated for 48 h. Cell proliferation was measured by a CCK-8 assay. ⁄P < 0.05,
⁄⁄P < 0.01 compared with vector, #P < 0.05, ##P < 0.01 compared with miR-150 + vector. All data represent the results of three independent experiments.
Fig. 4. Inhibition of miR-150 induces apoptosis. A549 cells were transiently transfected with scrambled control (A) or miR-150 (B) for 48 h. Apoptotic ratios were analyzed by
ﬂow cytometry, and data are shown in (C). ⁄⁄⁄P < 0.001 compared to the control. All data represent the results of three independent experiments.
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transcript at its 30UTR and inhibit its translation. Furthermore, we
also reverse the pro-proliferation effect of miR-150 by overexpres-
sion P53 in two different NSCLC cell lines, which extend our under-
standing of miR-150 in the pathogenesis of lung cancer.
In conclusion, our study provided evidence that the interaction
between miR-150 and P53 was important in the pathogenesis of
NSCLC and that miR-150 might be helpful in clinical diagnosis
and therapy.
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